These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26077360)

  • 21. Immunological effects of hypomethylating agents.
    Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
    Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
    Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
    Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
    Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
    Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
    Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.
    Odenike O
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):460-469. PubMed ID: 29222294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V
    Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
    Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
    Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
    Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
    Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
    Orsini P; Impera L; Parciante E; Cumbo C; Minervini CF; Minervini A; Zagaria A; Anelli L; Coccaro N; Casieri P; Tota G; Brunetti C; Ricco A; Carluccio P; Specchia G; Albano F
    Diagn Pathol; 2018 Dec; 13(1):98. PubMed ID: 30579366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
    Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
    Ørskov AD; Grønbæk K
    Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
    J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Demethylating medication in myelodysplastic syndrome].
    Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.
    Jung HA; Maeng CH; Kim M; Kim S; Jung CW; Jang JH
    Oncotarget; 2015 Jun; 6(18):16653-62. PubMed ID: 25938546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.